EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques

Nature Communications

Volumn 6, Issue , 2015, Pages

  Kim, Hye Yun ^a,b,c   Kim, Hyunjin Vincent ^a,b   Jo, Seonmi ^a   Lee, C Justin ^a   Choi, Seon Young ^a   Kim, Dong Jin ^a   Kim, Youngsoo ^a,b  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Goshen Biotech Inc   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEPROPANESULPHONIC ACID; 4 AMINOBUTYRIC ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; OLIGOMER; PRESENILIN 1; UNCLASSIFIED DRUG; N(2-HYDROXYTHYL)PIPERAZINE-N'-(3-PROPANESULFONIC ACID); PIPERAZINE DERIVATIVE;

ACID; BRAIN; COGNITION; EXPERIMENTAL STUDY; NERVOUS SYSTEM DISORDER; PHENOTYPE; RODENT;

4 AMINOBUTYRIC ACID RELEASE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; HIPPOCAMPUS; INFLAMMATION; MALE; MOUSE; NONHUMAN; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; ANIMAL; COGNITION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PSYCHOLOGY; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; PIPERAZINES; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84949599389     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9997     Document Type: Article

References (63)

1. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804 (2012).
2. Dineley, K. T. et al. Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J. Neurosci. Res. 88, 2923-2932 (2010).
3. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (2007).
4. Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J. & Drago, F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 73, 504-517 (2012).
5. Gervais, F. et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 28, 537-547 (2007).
6. McLaurin, J. et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801-808 (2006).
7. Yang, F. et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005).
8. Selkoe, D. J. Preventing Alzheimer's disease. Science 337, 1488-1492 (2012).
9. Selkoe, D. J. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060-1065 (2011).
10. Jack, Jr C. R. et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128 (2010).
11. Green, R. C. et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564 (2009).
12. Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698-712 (2011).
13. Kim, H. Y., Kim, Y., Han, G. & Kim, D. J. Regulation of in vitro Abeta1-40 aggregation mediated by small molecules. J. Alzheimers Dis. 22, 73-85 (2010).
14. Van Dam, D. & De Deyn, P. P. Animal models in the drug discovery pipeline for Alzheimer's disease. Br. J. Pharmacol. 164, 1285-1300 (2011).
15. Cao, D., Lu, H., Lewis, T. L. & Li, L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 282, 36275-36282 (2007).
16. Bryan, K. J., Lee, H., Perry, G., Smith, M. A. & Casadesus, G. in Methods of Behavior Analysis in Neuroscience. (eds Buccafusco, J. J.2nd edn, 2009).
17. Yan, P. et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281, 24566-24574 (2006).
18. Price, J. L. & Morris, J. C. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann. Neurol. 45, 358-368 (1999).
19. Morris, J. C. et al. Cerebral amyloid deposition and diffuse plaques in 'normal' aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46, 707-719 (1996).
20. Sarsoza, F. et al. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol. 118, 505-517 (2009).
21. Vina, J. & Lloret, A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J. Alzheimers Dis. 20(Suppl 2): S527-S533 (2010).
22. Ott, B. R., Lapane, K. L. & Gambassi, G. Gender differences in the treatment of behavior problems in Alzheimer's disease. SAGE Study Group. Systemic Assessment of Geriatric drug use via Epidemiology. Neurology 54, 427-432 (2000).
23. Heneka, M. T. Inflammation in Alzheimer's disease. Clin. Neurosci. Res. 6, 247-260 (2006).
24. Scott Bitner, R. Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer's disease therapeutics. Biochem. Pharmacol. 83, 705-714 (2012).
25. Jo, S. et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat. Med. 20, 886-896 (2014).
26. Noormagi, A., Primar, K., Tougu, V. & Palumaa, P. Interference of low-molecular substances with the thioflavin-T fluorescence assay of amyloid fibrils. J. Pept. Sci. 18, 59-64 (2012).
27. Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
28. Cleary, J. P. et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84 (2005).
29. Bitan, G. & Teplow, D. B. Rapid photochemical cross-linking-a new tool for studies of metastable, amyloidogenic protein assemblies. Acc. Chem. Res. 37, 357-364 (2004).
30. Richter, L. et al. Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc. Natl Acad. Sci. USA 107, 14597-14602 (2010).
31. O'Hare, E. et al. Orally bioavailable small molecule drug protects memory in Alzheimer's disease models. Neurobiol. Aging 34, 1116-1125 (2013).
32. Goverdhan, P., Sravanthi, A. & Mamatha, T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int. J. Alzheimers Dis. 2012, 974013 (2012).
33. Sinha, S. et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J. Am. Chem. Soc. 133, 16958-16969 (2011).
34. Legleiter, J. et al. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J. Mol. Biol. 335, 997-1006 (2004).
35. Frenkel, D., Katz, O. & Solomon, B. Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. USA 97, 11455-11459 (2000).
36. Puzzo, D. et al. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 69, 819-830 (2011).
37. Parihar, M. S. & Brewer, G. J. Amyloid-beta as a modulator of synaptic plasticity. J. Alzheimers Dis. 22, 741-763 (2010).
38. Morley, J. E. et al. A physiological role for amyloid-beta protein:enhancement of learning and memory. J. Alzheimers Dis. 19, 441-449 (2010).
39. Garcia-Osta, A. & Alberini, C. M. Amyloid beta mediates memory formation. Learn. Mem. 16, 267-272 (2009).
40. Grant, J. L. et al. Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci. Transl. Med. 4, 145ra105 (2012).
41. Fraser, P. E., Nguyen, J. T., Chin, D. T. & Kirschner, D. A. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J. Neurochem. 59, 1531-1540 (1992).
42. Ferrao-Gonzales, A. D. et al. Controlling {beta}-amyloid oligomerization by the use of naphthalene sulfonates: trapping low molecular weight oligomeric species. J. Biol. Chem. 280, 34747-34754 (2005).
43. Gauthier, S. et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging 13, 550-557 (2009).
44. Santa-Maria, I., Hernandez, F., Moreno, F. J. & Avila, J. Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. Neurosci. Lett. 429, 91-94 (2007).
45. Citron, M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387-398 (2010).
46. Paxinos, G. & Franklin, B. J. The Mouse Brain in Stereotaxic Coordinates 2nd edn (Academic Press, 2001).
47. Kim, H. V. et al. Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid 20, 7-12 (2013).
48. Meunier, J., Ieni, J. & Maurice, T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br. J. Pharmacol. 149, 998-1012 (2006).
49. Tsunekawa, H., Noda, Y., Mouri, A., Yoneda, F. & Nabeshima, T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav. Brain Res. 190, 224-232 (2008).
50. Fanselow, M. S. & Tighe, T. J. Contextual conditioning with massed versus distributed unconditional stimuli in the absence of explicit conditional stimuli. J. Exp. Psychol. Anim. Behav. Process. 14, 187-199 (1988).
51. LeDoux, J. E. Emotion: clues from the brain. Annu. Rev. Psychol. 46, 209-235 (1995).
52. Phillips, R. G. & LeDoux, J. E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 106, 274-285 (1992).
53. Curzon, P., Rustay, N. R. & Browman, K. E. in Methods of Behavior Analysis in Neuroscience 2nd edn (eds Buccafusco, J. J.) 2.19-2.37 (CRC Press, Boca Ranton, Florida, USA, 2009).
54. Wang, D. et al. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32, 1261-1271 (2007).
55. Morris, R. G., Garrud, P., Rawlins, J. N. & O'Keefe, J. Place navigation impaired in rats with hippocampal lesions. Nature 297, 681-683 (1982).
56. D'Hooge, R. & De Deyn, P. P. Applications of the Morris water maze in the study of learning and memory. Brain Res. Rev. 36, 60-90 (2001).
57. Li, Z., Herrmann, K. & Pohlenz, F. Lateral scanning confocal microscopy for the determination of in-plane displacements of microelectromechanical systems devices. Opt. Lett. 32, 1743-1745 (2007).
58. Dunah, A. W. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243 (2002).
59. Kim, Y. S., Moss, J. A. & Janda, K. D. Biological tuning of synthetic tactics in solid-phase synthesis: application to A beta(1-42). J. Org. Chem. 69, 7776-7778 (2004).
60. Kline, T. et al. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC. J. Med. Chem. 45, 3112-3129 (2002).
61. LeVine, 3rd H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410 (1993).
62. Nicoll, A. J. et al. Amyloid-beta nanotubes are associated with prion protein-dependent synaptotoxicity. Nat. Commun. 4, 2416 (2013).
63. Cannon, M. J., Williams, A. D., Wetzel, R. & Myszka, D. G. Kinetic analysis of beta-amyloid fibril elongation. Anal. Biochem. 328, 67-75 (2004).